ArticleEpilepsia2025
Choice of antiseizure medications and associated outcomes in Medicare beneficiaries after acute ischemic stroke.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Outcomes of patients with post-stroke epilepsy: A scoping review on quality of life, readmissions, costs, seizure recurrence, and medication adherence.Epilepsia open · 2026Review
- Association of atherogenic index of plasma and post-stroke epilepsy in patients with ischemic stroke: a multicenter retrospective study in China.Therapeutic advances in neurological disorders · 2026Article
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
objectiveWe examined choice of outpatient epilepsy-specific antiseizure medication (ESM) after a stroke discharge and outcomes in a sample of US older adults.
methodsIn this matched cohort study, we analyzed a 20% sample of US Medicare beneficiaries aged 65 years and older hospitalized for acute ischemic stroke (AIS) between 2009 and 2021 who were discharged home. Individuals met insurance coverage criteria and were not taking ESM before hospitalization. We matched individuals on days from discharge to ESM initiation. Individuals who initiated ESMs other than levetiracetam within 30 days of discharge (n = 229) were matched to levetiracetam initiators (n = 687). We did not include antiseizure medications used for treatment of pain or psychiatric disorders such as gabapentin and benzodiazepines. We investigated the time to seizurelike events, emergency department (ED) visits, and readmissions using a semicompeting risk framework.
resultsThe matched cohort of 916 ESM initiators had a median age of 73 years (interquartile range = 69-81) and was 57% female and 71% non-Hispanic White. Using the semicompeting risk framework, those who received other ESM had a 37% lower hazard of seizurelike events compared to those receiving levetiracetam, given that death had not occurred (hazard ratio = .63, 95% confidence interval [CI] = .43-.91). Among other ESM initiators, the hazard of ED visits and hospital readmissions, given that death had not occurred, did not differ significantly from initiating levetiracetam (hazard ratios = 1.00 [95% CI = .80-1.25] and .98 [95% CI = .75-1.28], respectively). SIGNIFICANCE: In a sample of US Medicare beneficiaries hospitalized for AIS and discharged home, initiating levetiracetam in the outpatient setting was associated with a higher risk of seizurelike events compared to other ESMs. However, there remains a possibility of residual confounding by indication, as individuals with greater risk of seizures may have been started on levetiracetam. We did not observe significant differences in the risk of ED visits or readmissions, suggesting comparable safety profiles in broader clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.